Ensysce Ends Q3 With $29.7M Cash, But MHRA Wants More Data on Lead CRPS Program
ENSC sits 68% above its 52-week low of $0.23.
Summary
Ensysce closed Q3 2026 with $29.7 million in cash, up from $4.3 million at year-end 2025, after $19.6 million in net Series C proceeds and $11.4 million acquired with Cy Biopharma. The reported $82.3 million net loss is almost entirely a one-time non-cash $79.9 million IPR&D charge tied to the Cy Biopharma acquisition, not operating burn — nine-month operating cash use was $6.9 million. The offsetting negative: on November 6 the MHRA and the reviewing ethics committee asked for additional information on the CY200 Phase 2a protocol, so the UK study cannot start until that response clears. Enrollment is complete in Part 3 of PF614-MPAR-102, with $2.7 million left on the $15.1 million NIDA award to finish the study and long-term non-clinical work. The December 14 annual meeting and the December 23 proxy vote on converting Series C preferred into roughly 358.3 million shares remain the dominant overhang on the share count.
At the time of this announcement, ENSC was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.23 to $2.17. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.